The role of inflammation in brain cancer

• Published in: Advances in experimental medicine and biology Vol. 816; p. 75
• Main Authors: Sowers, James L, Johnson, Kenneth M, Conrad, Charles, Patterson, Joel T, Sowers, Lawrence C
• Format: Journal Article
• Language: English
• Published: United States 01.01.2014
• Subjects: Animals; Brain Neoplasms - etiology; Brain Neoplasms - therapy; Cell Transformation, Neoplastic - genetics; Cell Transformation, Neoplastic - immunology; Epigenesis, Genetic; Glioblastoma - etiology; Glioblastoma - therapy; Humans; Inflammation - complications; Inflammation - genetics; Inflammation - therapy; Receptor Protein-Tyrosine Kinases - physiology; Signal Transduction - genetics
• ISSN: 0065-2598
• DOI: 10.1007/978-3-0348-0837-8_4

Malignant brain tumors are among the most lethal of human tumors, with limited treatment options currently available. A complex array of recurrent genetic and epigenetic changes has been observed in gliomas that collectively result in derangements of common cell signaling pathways controlling cell survival, proliferation, and invasion. One important determinant of gene expression is DNA methylation status, and emerging studies have revealed the importance of a recently identified demethylation pathway involving 5-hydroxymethylcytosine (5hmC). Diminished levels of the modified base 5hmC is a uniform finding in glioma cell lines and patient samples, suggesting a common defect in epigenetic reprogramming. Within the tumor microenvironment, infiltrating immune cells increase oxidative DNA damage, likely promoting both genetic and epigenetic changes that occur during glioma evolution. In this environment, glioma cells are selected that utilize multiple metabolic changes, including changes in the metabolism of the amino acids glutamate, tryptophan, and arginine. Whereas altered metabolism can promote the destruction of normal tissues, glioma cells exploit these changes to promote tumor cell survival and to suppress adaptive immune responses. Further understanding of these metabolic changes could reveal new strategies that would selectively disadvantage tumor cells and redirect host antitumor responses toward eradication of these lethal tumors.